Roche racks up phase 3 TIGIT win, but trial design leaves doubts

Roche has bagged a phase 3 win in TIGIT. But the victory falls short of being a clear-cut endorsement of the mechanism, with the use of a comparator that is no longer the standard of care complicating efforts to tease out the impact of the investigational antibody.